Last-Resort drug access opens for aggressive breast cancer patients
NCT ID NCT07536815
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides early access to an experimental drug called leronlimab for people with advanced triple-negative breast cancer who have run out of standard treatments. Participants must be adults with stage IIIB or IV cancer that has worsened despite prior therapy. The goal is to offer a potential treatment option when no others are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oregon Oncology Specialists
AVAILABLESalem, Oregon, 97301, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers